Albert Labs

📍 London, United Kingdom🗓 Founded 2020👥 8 employees💰 Last funded Mar 2022
Biotechnology Research🌐 albertlabs.com
Website LinkedIn
Albert Labs (CSE: ABRT) is a bio-pharmaceutical company pursuing licensing approval for active compounds from natural sources; providing access to effective prescription medicines for people suffering from mental health disorders. Our team of drug development experts leverage advanced culture technology and extraction methods to produce unique and effective natural medicines. We develop clinical solutions through an approved, fast track regulatory pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized clinical access route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, we utilise existing clinical infrastructure to deliver and improve patient access to their treatment. Our first drug target, KRN-101 for a potential solution for cancer-related anxiety, will support an initial market of over 15 million people with an estimated 1 million new sufferers each year.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Albert Labs?
Albert Labs has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Albert Labs last raise funding?
The most recent investment in Albert Labs recorded on gritt.io was in March 2022.
When was Albert Labs founded?
Albert Labs was founded in 2020.
What industry is Albert Labs in?
Albert Labs operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Albert Labs based?
Albert Labs is headquartered in London, United Kingdom.